Hervé Affagard (Co-founder and CEO)
Hervé Affagard is the CEO of MaaT Pharma, a company specialised in the treatment of intestinal microbiota dysbiosis secondary to medical treatments. MaaT Pharma is developing a safe and standardized process for autologous fecal microbiota transplant aiming at preventing and treating dysbiosis associated to certain infectious diseases in patients receiving massive dose of antibiotics. MaaT Pharma benefits from INRA know-how, a worldwide leader in the intestinal microbiota knowledge, which helps in the research of medical applications based on its work.
Hervé Affagard leads the MaaT Pharma project since its inception in December 2014. Hervé worked previously as an entrepreneur in residence for venture capital firms with regards to their investments in the Healthcare field. In parallel, he also used to work as a consultant for biotechnology companies where he led transformation programs. He was previously an executive director leading a multidisciplinary team at Biomnis, specialist in medical testing. Combined with his previous experience at Bio-Rad which serves life science research and clinical diagnostics customers, he brings to MaaT Pharma a strong track record of operational leadership in the health sector and the capacity to translate into a concrete plan medical notions.
Hervé is an Engineer, Executive MBA, and holds a certificate “Exploring your Microbiome”.